Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced second-quarter 2026 net product revenue of approximately $13.5 million, a significant increase from $2 million in the year-ago period, largely attributed to $11 million in net sales of TONMYA, its recently approved fibromyalgia treatment. The company reported 12,592 total prescriptions for TONMYA during the quarter, a 100% sequential increase, with new patient prescriptions up 36% and refills rising 207%. This growth underscores the drug's market acceptance and the effectiveness of Tonix's commercial infrastructure.
TONMYA's market access has expanded substantially, now covering approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. The company expects coverage to reach about 145 million lives when a managed Medicare agreement takes effect on January 1, 2027. This broadening coverage is critical for the drug's continued uptake and revenue growth.
Beyond TONMYA's commercial success, Tonix is actively advancing its clinical pipeline. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study evaluating TNX-102 SL for major depressive disorder, a condition with significant unmet need. Additionally, Tonix is preparing to initiate an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. These programs highlight Tonix's commitment to addressing high unmet medical needs in CNS and immunology.
Financially, Tonix ended the quarter with approximately $176.2 million in cash and cash equivalents. Management stated that these resources, along with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This runway provides the company with the stability to execute its commercial and clinical strategies.
The strong performance of TONMYA is particularly notable as it is the first new treatment for fibromyalgia in over 15 years. Fibromyalgia affects millions of patients, and TONMYA's differentiated profile as a sublingual cyclobenzaprine formulation offers a new option for managing this chronic pain condition. The robust prescription growth and expanding coverage indicate that TONMYA is gaining traction among physicians and patients, which could position it as a leading therapy in the fibromyalgia market.
Tonix's broader portfolio includes other CNS products such as Zembrace SymTouch and Tosymra for acute migraine, as well as investigational candidates like TNX-2900 for Prader-Willi syndrome. In immunology, the company is developing TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for kidney transplant rejection prevention. These diverse programs spread risk and offer multiple catalysts for future value creation.
The company's progress in both commercial sales and pipeline development is a positive signal for investors. The significant revenue jump and the potential of the pipeline to address large markets could drive long-term growth. As TONMYA continues to gain market share and the pipeline advances, Tonix is positioning itself as a key player in the biotechnology sector, focusing on areas where effective treatments are limited.
For more details on the full press release, visit https://ibn.fm/6Yytj. For the latest news and updates on Tonix Pharmaceuticals, see the company's newsroom at https://ibn.fm/TNXP.
